drugset
Drugs / tyrosinase peptide
last change Jan 2013 re-read 9 days ago

tyrosinase peptide

also known as tyrosinase · tyrosinase:206-214 · tyrosinase:240-251 (244S) · tyrosinase:368-376 (370D)

Peptide

Developed for
cutaneous melanoma · ocular melanoma · iris melanoma · medium/large size posterior uveal melanoma · ocular melanoma with extraocular extension · melanoma · mucosal melanoma · small size posterior uveal melanoma
Investigated by
National Cancer Institute (NCI) · University of Southern California · Memorial Sloan Kettering Cancer Center · Duke University · Herbert Irving Comprehensive Cancer Center · University of Virginia

Trials 18

today NCT00089063 · Ph 2 NCT00085189 · Ph 2 NCT00334776 · Ph 2 NCT00031733 · Ph 2 NCT00037037 · Ph 1 NCT00006243 · not/applicable NCT00020358 · Ph 2 NCT00005841 · Ph 1 NCT01989572 · Ph 3 NCT00005633 · Ph 1 NCT00006113 · Ph 2 NCT00003339 · Ph 2 NCT00003362 · Ph 2 NCT00003222 · Ph 2 NCT00003274 · Ph 2 NCT00019396 · Ph 2 NCT00019383 · Ph 2 NCT00003229 · Ph 1/2
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT00037037 Oct 2001 → ? cutaneous melanoma Herbert Irving Comprehensive Cancer Center Unknown No outcome recorded
Phase 1 NCT00005841 Jun → Dec 2000 cutaneous melanoma, ocular melanoma University of Southern California Terminated No outcome recorded
Phase 1 NCT00005633 Jun 1999 → Jun 2002 cutaneous melanoma Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00003229 Jul 1997 → Apr 2000 cutaneous melanoma Duke University Completed No outcome recorded
Phase 212 trials
Phase 2 NCT00089063 Jun 2004 → Jun 2007 iris melanoma, medium/large size posterior uveal melanoma, ocular melanoma with extraocular extension National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00085189 May 2004 → Sep 2007 iris melanoma, medium/large size posterior uveal melanoma, mucosal melanoma, ocular melanoma with extraocular extension +1 University of Southern California Completed No outcome recorded
Phase 2 NCT00334776 Oct 2003 → Jun 2005 cutaneous melanoma, ocular melanoma University of Southern California Completed No outcome recorded
Phase 2 NCT00031733 Feb 2002 → Dec 2004 cutaneous melanoma, ocular melanoma University of Southern California Completed No outcome recorded
Phase 2 NCT00020358 Sep 2000 → Oct 2007 cutaneous melanoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00006113 Jun 1999 → May 2003 cutaneous melanoma University of Southern California Terminated No outcome recorded
Phase 2 NCT00003339 Nov 1998 → Nov 1999 cutaneous melanoma, ocular melanoma University of Southern California Completed No outcome recorded
Phase 2 NCT00003362 May 1998 → Feb 2001 cutaneous melanoma Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 2 NCT00003222 Apr 1998 → Sep 2003 cutaneous melanoma University of Virginia Completed No outcome recorded
Phase 2 NCT00003274 Mar 1998 → Sep 2001 cutaneous melanoma University of Southern California Completed No outcome recorded
Phase 31 trial · 1 missed
Phase 3 NCT01989572 Feb 2000 → Oct 2012 cutaneous melanoma, iris melanoma, medium/large size posterior uveal melanoma, mucosal melanoma +2 National Cancer Institute (NCI) Completed Missed primary
Phase not applicable1 trial
— NCT00006243 Oct 2000 → May 2006 melanoma National Cancer Institute (NCI) Completed No outcome recorded
Comparator or background therapy2 trials
Phase 1 NCT00025181 Background Oct 2001 → Jan 2003 cutaneous melanoma, ocular melanoma University of Southern California Completed No outcome recorded
Phase 1 NCT00003665 Background Apr 1999 → Oct 2002 cutaneous melanoma National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 21 sources stand behind the page.

FieldValueCited text
Known as tyrosinase peptide ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003339 ↗
19

NCT01989572 ↗

NCT00003229 ↗

NCT00003665 ↗

NCT00003222 ↗

NCT00005633 ↗

NCT00085189 ↗

NCT00019396 ↗

NCT00020358 ↗

NCT00006243 ↗

NCT00334776 ↗

Show 9 more sources
Known as tyrosinase “The melanoma tumor antigen epitope peptides MART-1(26-35 (27L)), gp100(209-217 (210M)),and tyrosinase(368-376 (370D)) were emulsified with incomplete Freund's adjuvant and...” PMID 12684398 ↗ Apr 2003
Known as tyrosinase:206-214 “tyrosinase:368-376 (370D), tyrosinase:240-251 (244S), tyrosinase:206-214 (closed to accrual 11/05/01)” NCT00020358 ↗
Known as tyrosinase:240-251 (244S) “tyrosinase:368-376 (370D), tyrosinase:240-251 (244S), tyrosinase:206-214 (closed to accrual 11/05/01)” NCT00020358 ↗
Known as tyrosinase:368-376 (370D) “tyrosinase:368-376 (370D), tyrosinase:240-251 (244S), tyrosinase:206-214 (closed to accrual 11/05/01)” NCT00020358 ↗
Action Deplete “Vaccines made from peptides may make the body build an immune response to kill tumor cells.” NCT00089063 ↗
Modality Peptide “mixture of synthetic melanoma peptides” NCT00003222 ↗
Route Subcutaneous “vaccine comprising tyrosinase peptide and gp100 antigen emulsified in Montanide ISA-51 (ISA-51) alone subcutaneously (SQ) once a week” NCT00003274 ↗